A pragmatic clinical trial assessing the effect of a targeted notification and clinical support pathway on the diagnostic evaluation and treatment of individuals with left ventricular hypertrophy (NOTIFY-LVH) - 11/10/23
Résumé |
Background |
Electronic health records contain vast amounts of cardiovascular data, including potential clues suggesting unrecognized conditions. One important example is the identification of left ventricular hypertrophy (LVH) on echocardiography. If the underlying causes are untreated, individuals are at increased risk of developing clinically significant pathology. As the most common cause of LVH, hypertension accounts for more cardiovascular deaths than any other modifiable risk factor. Contemporary healthcare systems have suboptimal mechanisms for detecting and effectively implementing hypertension treatment before downstream consequences develop. Thus, there is an urgent need to validate alternative intervention strategies for individuals with preexisting—but potentially unrecognized—LVH.
Methods |
Through a randomized pragmatic trial within a large integrated healthcare system, we will study the impact of a centralized clinical support pathway on the diagnosis and treatment of hypertension and other LVH-associated diseases in individuals with echocardiographic evidence of concentric LVH. Approximately 600 individuals who are not treated for hypertension and who do not have a known cardiomyopathy will be randomized. The intervention will be directed by population health coordinators who will notify longitudinal clinicians and offer to assist with the diagnostic evaluation of LVH. Our hypothesis is that an intervention that alerts clinicians to the presence of LVH will increase the detection and treatment of hypertension and the diagnosis of alternative causes of thickened myocardium. The primary outcome is the initiation of an antihypertensive medication. Secondary outcomes include new hypertension diagnoses and new cardiomyopathy diagnoses. The trial began in March 2023 and outcomes will be assessed 12 months from the start of follow-up.
Conclusion |
The NOTIFY-LVH trial will assess the efficacy of a centralized intervention to improve the detection and treatment of hypertension and LVH-associated diseases. Additionally, it will serve as a proof-of-concept for how to effectively utilize previously collected electronic health data to improve the recognition and management of a broad range of chronic cardiovascular conditions.
Trial Registration |
NCT05713916.
Le texte complet de cet article est disponible en PDF.Keywords : Left ventricular hypertrophy, LVH, Pragmatic clinical trial, Cardiovascular population health, Undiagnosed hypertension, Cardiomyopathies
Plan
Vol 265
P. 40-49 - novembre 2023 Retour au numéro
Article précédent
- Efficacy and safety of a bolus of half-dose r-SAK prior to primary PCI in ST-elevation myocardial infarction: Rationale and design of the OPTIMA-6 trial
- Chen Li, John W Eikelboom, Zihang Zhong, Xiwen Zhang, Kun Liu, Li Zhu, Naiquan Yang, Xin Chen, Xiaoyan Wang, Xin Zhao, Jun Jiang, Jun Pu, Bo Zhao, Fumin Zhang, Jun Zhu, Jun Huang, Xiangqing Kong, Hao Yu, Chunyue Tan, Wenhao Zhang, Qin Wang, Xiaoxuan Gong, Jianling Bai, Chunjian Li, Nanjing, China
- Transforming blood pressure control in primary care through a novel remote decision support strategy based on wearable blood pressure monitoring: The NEXTGEN-BP randomized trial protocol
- Sonali R Gnanenthiran, Isabella Tan, Emily R Atkins, Alberto Avolio, Belinda Bennett, Niamh Chapman, Clara K Chow, Ruth Freed, Danijela Gnjidic, Charlotte Hespe, Baldeep Kaur, Huei Ming Liu, Anushka Patel, David Peiris, Christopher M Reid, Markus Schlaich, James E. Sharman, George S. Stergiou, Tim Usherwood, Christopher Gianacas, Anthony Rodgers, Aletta E Schutte
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?